953 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Bought by True Wealth Design LLC

True Wealth Design LLC bought a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 953 shares of the company’s stock, valued at approximately $27,000.

Other large investors have also recently added to or reduced their stakes in the company. Wolverine Asset Management LLC acquired a new stake in Apellis Pharmaceuticals in the 3rd quarter valued at $27,000. Capital Performance Advisors LLP acquired a new stake in shares of Apellis Pharmaceuticals in the third quarter valued at about $56,000. KBC Group NV raised its holdings in Apellis Pharmaceuticals by 34.8% during the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after acquiring an additional 679 shares in the last quarter. nVerses Capital LLC boosted its position in Apellis Pharmaceuticals by 300.0% during the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after purchasing an additional 2,100 shares during the last quarter. Finally, CWM LLC grew its stake in Apellis Pharmaceuticals by 299.9% in the second quarter. CWM LLC now owns 4,151 shares of the company’s stock valued at $159,000 after purchasing an additional 3,113 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on APLS shares. Wedbush lifted their price objective on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Mizuho lowered their price target on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a research report on Thursday, October 24th. JPMorgan Chase & Co. dropped their price objective on Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating on the stock in a research note on Friday, September 13th. William Blair began coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They set an “outperform” rating for the company. Finally, The Goldman Sachs Group dropped their price target on Apellis Pharmaceuticals from $71.00 to $36.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.94.

Insider Transactions at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the sale, the director now owns 100,000 shares in the company, valued at approximately $3,623,000. This trade represents a 27.01 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 6.80% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ:APLS opened at $35.42 on Tuesday. Apellis Pharmaceuticals, Inc. has a 12-month low of $24.34 and a 12-month high of $73.80. The company’s 50 day moving average price is $28.77 and its two-hundred day moving average price is $35.20. The firm has a market cap of $4.41 billion, a PE ratio of -17.45 and a beta of 0.87. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The company had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company’s quarterly revenue was up 78.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.17) EPS. Equities research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current year.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).